Weekly Recap | Caredex -1.22%, most brokers rate it buy

The Week

Caredex (CDNA) eased 1.22% over the four-session week to close at $50.26, underperforming the S&P 500’s 0.8% decline by about 0.42 percentage point. The week’s trading range was 6.04%. After opening at $50.50 on Tuesday, the stock touched a weekly high of $51.33 on Wednesday and a low of $48.64 on Thursday before settling back above $50, with Friday’s session finishing at $50.26 in narrow range action. There was no major company-specific catalyst, with just one media note centred on the transplant growth narrative and whether the valuation remains compelling.

Analyst Ratings

Among the 8 brokers covering Caredex, 5 rate it buy and 3 rate it hold, with no sell or underweight ratings. Consensus stands at buy, with a target of $54.14, roughly 7.7% above the latest price of $50.26. Target range runs from $40 to $65, a wide spread that highlights disagreement on valuation. Within the biotech industry, the stock ranks 189th out of 506 names by analyst rating.

The Week Ahead

Next week brings a concentrated run of US macro data. Tuesday features the New York Fed manufacturing index, with a prior reading of 20.6 and consensus at 14.75. On Wednesday, retail sales, retail sales ex-autos, retail control, import prices and the NAHB housing market index all land together. Retail sales ex-autos has a prior of -0.3 and consensus of 0.6, while retail sales had a prior of -0.6 and consensus of 0.9. The EIA weekly crude and Cushing inventories also arrive on Wednesday. Caredex itself has no earnings or calendar events, so next week’s direction will hinge more on macro-driven shifts in risk appetite.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.